BMS: Retaining Top Talent Through An Acquisition And A Pandemic
Executive Summary
Catherine Owen joined Bristol Myers Squibb in September 2019, tasked with overseeing the integration of Celgene and BMS’s international businesses. She talks to In Vivo about managing the merger of teams from two very distinct companies during a global pandemic. Owen, who is passionate about career growth and mentoring, also highlights the importance of talent development and sponsorship – even in times of uncertainty, when business as usual goes out the window.
You may also be interested in...
In Vivo’s 2021 Rising Leaders: Recognizing Talent Across The Life Sciences
Revealed: In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors. Find out who is in the spotlight this year.
Putting Affordable Innovation Center Stage
Sarah Howell, one of In Vivo’s 2021 Rising Leaders, was appointed CEO of Arecor in 2015 and has led the company’s transformation into a successful clinical-stage biotechnology company. In an exclusive interview, Howell described Arecor as focused on “affordable innovation,” particularly in disease areas with large and growing patient populations, such as diabetes.
30 Life Sciences Leaders To Watch In 2021
30 Rising Leaders who are making waves and challenging traditional structures across the biopharma and medtech sectors. In Vivo's 2021 list also includes industry stars that have raised their game in response to the COVID-19 pandemic.